
11 Introduction

15 Biotechnology Market Abstract

17 Biotech Approaches 40: Going Middle-Age Crazy or Aging Gracefully?

17 The Contemporary Biotech Drug Development (Emotional) Cycle

17 This Is the Decade

19 Gene Therapy Is Set to Redefine the Industry and World

19 You Say You Want a Revolution, Well, You Know . . . Bio-Innovation

20 Biotechnology Grows into its Adult Future

21 Looking for a Bellwether? Do as Pharma Does

23 Biotechnology Timeline

25 Through the Biotech Market Years

26 Timeline for the Modern Biotechnology Market

35 The Market-Leading Biotech Drugs

37 Biotech's Best Decade Ever Will be All About the Drugs

43 Profiles of the Market-Leading Biotech Drugs

45 Biotechnology Drugs Are Set to Continue Their Rule

47 1. Avastin

49 2. Rituxan

51 3. Humira

53 4. Herceptin

55 5. Remicade

57 6. Gleevec

59 7. Enbrel

61 8. Neulasta

63 9. Lantus

65 10. Tamiflu

67 11. Copaxone

69 12. Aranesp

71 13. Epogen

73 14. Truvada

75 15. Neupogen

77 16. Avonex

79 17. Atripla

81 18. Procrit/Epex

83 19. Taxotere

85 20. Rebif

87 21. Humalog

89	22. Alimta
91	23. Betaseron
93	24. Erbitux
95	25. Cialis
<hr/>	
109	2010 State of the Industry
<hr/>	
111	Analysis
113	Mid-Year Upsurge Saves 2009, Stoking Hope for the Year to Come
115	Industry Rebounds Amid Strong Data, Cautious Optimism in 2009
117	Stimulus Funds Opened Opportunities; H1N1 Plagued Feds
119	Cash-Starved EU, UK Industry Seeing Reasons for Fresh Hope
121	HIV Vaccine, Gene Therapies Among 2009's Big Advances
<hr/>	
125	Financial Data
127	After Slow Start, 2009 Finishes Strong for Biotech Fundraising
<hr/>	
221	Corporate Deals
223	Vaccines, Antibodies Spurred Flurry of M&A Activity Over Past Year
<hr/>	
373	Biotech Product Development
<hr/>	
437	Report Card for Wall Street
439	Methodology Used To Evaluate Underwriters' Performance
<hr/>	
453	Stock Performance
<hr/>	
461	Restructurings
<hr/>	
485	Lawsuits
<hr/>	

15	Biotechnology Market Abstract
18	Global Pharmaceutical and Biotech Industry Sales and Projection, 2005-2015
35	The Top 25 Biotech Drugs
37	Top 10 Products by Estimated Sales in 2014
38	Blockbusters Expected to Lose Patent Exclusivity
39	Biotech Drug Approvals, 1982 to 2009
40	Revenue of the Market-Leading Biotech Drugs in 2009
41	Revenue of the Top Biotech Drugs, 2003-2009
42	Top 10 Generics Companies
42	The Top Most Valuable R&D Projects
109	2010 State of the Industry
125	Financial Data
129	Money Raised by Biotech in 2009: January – December
130	January – December 2009 Initial Public Offerings
132	January – December 2009 Follow-On Offerings
138	After-Market Performance: IPO Class of 2009
139	After-Market Performance: Follow-On Class of 2009
142	2009 Initial Public Offerings
142	2008 Initial Public Offerings
142	2007 Initial Public Offerings
142	2006 Initial Public Offerings
143	2009 Follow-on Offerings
143	2008 Follow-on Offerings
143	2007 Follow-on Offerings
143	2006 Follow-on Offerings
144	Gross Proceeds of Biotech Public Stock Offerings First Through Fourth Quarter 1998-2009, Initial and Follow-on Offerings Combined
145	2009 Miscellaneous Financings of Public Biotech Companies
173	2009 Venture Capital And Other Financings Of Private Biotechnology Firms
193	2009 Milestone Payment From Corporate Partners
202	2009 Grants, Contracts And Awards To Biotech Companies
221	Corporate Deals
227	2009 Biotechnology Mergers And Acquisitions
240	2009 Biotech-Big Pharma Collaborations
274	2009 Biotech - Big Pharma Collaborations: Modified And Terminated Agreements
283	2009 Manufacturing, Marketing And Distribution Agreements Between Biotechnology Companies

291	2009 Biotechnology Company Collaborations With Other Biotechnology Companies
323	2009 Biotech - Biotech Collaborations: Modified And Terminated Agreements
329	2009 Manufacturing, Marketing And Distribution Agreements Between Biotechnology Companies
337	2009 Biotech Collaborations With Miscellaneous Companies
339	2009 Deals, Other Actions in Agriculture and Animals
341	2009 Collaborations Between Biotechnology Companies and Universities/Nonprofit Institutions

373 Biotech Product Development

374	Biotechnology Products Approved By The FDA In 2009
381	Biotechnology Products On The Market
404	FDA Actions On Pending Applications In 2009
410	Licensing Applications Filed And Pending At FDA In 2009
419	Recommendations By FDA Advisory Panels In 2009
422	Overseas Approvals And Other Regulatory Actions In 2009
432	Orphan Designations Granted In 2009

437 Report Card for Wall Street

440	Top 10 Underwriters For 2009 By Gross Proceeds: All Public Offerings; Full Credit To Lead Underwriters
441	Other Underwriters For 2009 By Gross Proceeds: All Public Offerings; Full Credit To Lead Underwriters
442	Top 10 Underwriters For 2009 By Gross Proceeds: All Public Offerings; Full Credit To All Underwriters
443	Other Underwriters For 2009 By Gross Proceeds: All Public Offerings; Full Credit To All Underwriters
444	Underwriters For 2009 By Gross Proceeds: Initial Public Offerings; Full Credit To Lead Underwriters
445	Underwriters For 2009 By Gross Proceeds: Initial Public Offerings; Full Credit To All Underwriters
446	Underwriters For 2009 By After-Market Performance: Initial Public Offerings; Full Credit To Lead Underwriters
447	Underwriters For 2009 By After-Market Performance: Initial Public Offerings; Full Credit To All Underwriters
448	Top 10 Underwriters For 2009 By After-Market Performance: All Public Offerings; Full Credit To Lead Underwriters
449	Other Underwriters For 2009 By After-Market Performance: All Public Offerings; Full Credit To Lead Underwriters
450	Top 10 Underwriters For 2009 By After-Market Performance: All Public Offerings; Full Credit To All Underwriters

451 Other Underwriters For 2009 By After-Market Performance: All Public Offerings; Full Credit To All Underwriters

453 Stock Performance

455 2009 U.S. Biotechnology Stock Report

457 2009 British Biotechnology Stock Report

458 2009 Canadian Biotechnology Stock Report

461 Restructurings

463 Bankrupt, Liquidated and Shut-Down Biotechs: 2009

463 Biotech Restructurings, Scale-Backs, Bankruptcies: January 1 - December 31, 2009

485 Lawsuits

487 Biotech Lawsuits: Jan. 1 - Dec. 31, 2009
